Voyageur Pharmaceuticals Stock Net Income
| VM Stock | CAD 0.18 0.01 5.88% |
Fundamental analysis of Voyageur Pharmaceuticals allows traders to better anticipate movements in Voyageur Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.5 M | -1.5 M | |
| Net Loss | -1.5 M | -1.6 M | |
| Net Loss | -1.8 M | -1.8 M | |
| Net Loss | (0.05) | (0.05) | |
| Net Income Per E B T | 0.90 | 0.80 |
Voyageur | Net Income |
Voyageur Pharmaceuticals Company Net Income Analysis
Voyageur Pharmaceuticals' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Voyageur Pharmaceuticals Net Income | (1.71 M) |
Most of Voyageur Pharmaceuticals' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Voyageur Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Voyageur Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Voyageur Pharmaceuticals is extremely important. It helps to project a fair market value of Voyageur Stock properly, considering its historical fundamentals such as Net Income. Since Voyageur Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Voyageur Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Voyageur Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Voyageur Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Voyageur Pharmaceuticals reported net income of (1.71 Million). This is 85.81% lower than that of the Pharmaceuticals sector and 100.14% lower than that of the Health Care industry. The net income for all Canada stocks is 100.3% higher than that of the company.
Voyageur Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Voyageur Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Voyageur Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Voyageur Pharmaceuticals by comparing valuation metrics of similar companies.Voyageur Pharmaceuticals is currently under evaluation in net income category among its peers.
Voyageur Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Voyageur Pharmaceuticals from analyzing Voyageur Pharmaceuticals' financial statements. These drivers represent accounts that assess Voyageur Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Voyageur Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 2.8M | 8.5M | 7.5M | 8.9M | 8.1M | 4.5M | |
| Enterprise Value | 3.1M | 7.8M | 7.5M | 8.8M | 7.9M | 4.4M |
Voyageur Fundamentals
| Return On Equity | -2.62 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (96.25) % | ||||
| Current Valuation | 30.32 M | ||||
| Shares Outstanding | 178.44 M | ||||
| Shares Owned By Insiders | 8.44 % | ||||
| Shares Owned By Institutions | 0.33 % | ||||
| Number Of Shares Shorted | 10 K | ||||
| Price To Book | 21.64 X | ||||
| Price To Sales | 2,909 X | ||||
| Gross Profit | (2.83 K) | ||||
| EBITDA | (2.51 M) | ||||
| Net Income | (1.71 M) | ||||
| Cash And Equivalents | 27.59 K | ||||
| Total Debt | 2.15 M | ||||
| Debt To Equity | 28.10 % | ||||
| Current Ratio | 0.16 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (302.29 K) | ||||
| Short Ratio | 0.08 X | ||||
| Earnings Per Share | (0.02) X | ||||
| Target Price | 0.55 | ||||
| Beta | 0.86 | ||||
| Market Capitalization | 32.12 M | ||||
| Total Asset | 2.6 M | ||||
| Retained Earnings | (10.84 M) | ||||
| Working Capital | (1.74 M) | ||||
| Net Asset | 2.6 M |
About Voyageur Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Voyageur Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Voyageur Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Voyageur Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Voyageur Stock Analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.